IL6 and cancer: In network pharmacology research, GO and KEGG enrichment analyses revealed that the potential mechanisms of methylprednisolone treatment for TMG mainly focus on proteoglycan-related cancer pathways and tumor necrosis factor-alpha (TNF-α) pathways, involving therapeutic targets such as tumor necrosis factor (TNF) and interleukin-6 (IL-6).